Aktis Oncology has initiated a Phase 1b clinical trial for AKY-2519, a targeted radioconjugate aimed at treating metastatic castration-resistant prostate cancer (mCRPC) expressing B7-H3. This trial includes patients both new to and experienced with PLUVICTO® therapy, with preliminary results expected in 2027. The company also plans a second Phase 1b basket trial for other B7-H3 expressing solid tumors like lung and colorectal cancers later in 2026, aiming to broaden treatment options and gather robust clinical data. This development addresses unmet needs in prostate cancer treatment, especially for patients ineligible or unresponsive to current PSMA-targeted therapies.
Entries for the Global Sustainability Awards 2026 close on June 29, recognizing excellence in sustainability across eight categories including enterprise, innovation, and environmental impact. The awards highlight businesses and individuals driving m...
Bio Usawa, a biotech firm focused on expanding access to biologic medicines in Africa, has appointed Dr. Aida Habtezion, former Chief Medical Officer at Pfizer, to its Board of Directors. Her expertise in global medical leadership and innovation will...
InterDigital, a leader in wireless, video, and AI technology, will present its latest innovations at the 13th FOKUS Media Web Symposium in Berlin, June 16-17, 2026. The company will demonstrate AI-enabled Pixel Value Reduction technology for energy-e...
Orange announced its intention to issue new perpetual hybrid bonds with a fixed adjustable interest rate and to launch a buyback offer for certain existing hybrid bonds. The new bonds are expected to be rated BBB-/Baa3/BBB- and traded on Euronext Par...
Orange announced its intention to issue new Euro-denominated hybrid notes with a 7-year non-call period and fixed-to-reset rates, expected to be rated BBB-/Baa3/BBB-. Simultaneously, the company is launching a tender offer to repurchase some of its o...
